

## KENYA – PENTAVALENT VACCINE SUPPORT

**This Decision Letter sets out the Programme Terms of a Programme.**

|   |                              |               |                    |
|---|------------------------------|---------------|--------------------|
| <b>1. Country:</b> Kenya  |                              |               |                    |
| <b>2. Grant Number:</b> 0715-KEN-04c-X  |                              |               |                    |
| <b>3. Date of Decision Letter:</b> 18 December 2014   |                              |               |                    |
| <b>4. Date of the Partnership Framework Agreement:</b> 25 November 2014   |                              |               |                    |
| <b>5. Programme Title:</b> New Vaccine Support  |                              |               |                    |
| <b>6. Vaccine type:</b> Pentavalent   |                              |               |                    |
| <b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 10 dose(s) per vial, LIQUID  |                              |               |                    |
| <b>8. Programme Duration<sup>1</sup>:</b> 2001 - 2015   |                              |               |                    |
| <b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>          |                              |               |                    |
|   | 2001-2014                    | 2015          | Total <sup>2</sup> |
| Programme Budget (US\$)   | US\$152,430,203 <sup>3</sup> | US\$9,236,000 | US\$161,666,203    |
| <b>10. Vaccine Introduction Grant:</b> n/a  |                              |               |                    |
| <b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b> |                              |               |                    |
| Type of supplies to be purchased with Gavi funds in each year   | 2001-2014                    | 2015          |                    |
| Number of Pentavalent vaccines doses  |                              | 4,526,500     |                    |
| Number of AD syringes   |                              | 5,726,300     |                    |
| Annual Amounts (US\$)   | US\$152,430,203 <sup>5</sup> | US\$9,236,000 |                    |
| <b>12. Procurement agency:</b> UNICEF   |                              |               |                    |

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

<sup>5</sup> This is the consolidated amount for all previously approved years.

|  |               |
|--|---------------|
| <b>13. Self-procurement:</b> n/a   |               |
| <b>14. Co-financing obligations:</b> Reference code: 0715-KEN-04c-X-C  |               |
| According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year. |               |
| Type of supplies to be purchased with Country funds in each year   | 2015          |
| Number of vaccine doses  | 1,147,500     |
| Value of vaccine doses (US\$)  | US\$2,195,017 |
| Total Co-Financing Payments (US\$) (including freight)   | US\$2,270,000 |
| <b>15. Operational support for campaigns:</b> n/a  |               |
| <b>16. Additional documents to be delivered for future disbursements:</b>  |               |
| Reports, documents and other deliverables  | Due dates     |
| Annual Progress Report or its equivalent   | 15 May 2015   |
| <b>17. Financial Clarifications:</b> n/a   |               |
| <b>18. Other conditions:</b> n/a   |               |

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
18 December 2014

## KENYA - PNEUMOCOCCAL VACCINE SUPPORT

**This Decision Letter sets out the Programme Terms of a Programme.**

|   |                              |                |                    |
|---|------------------------------|----------------|--------------------|
| <b>1. Country:</b> Kenya  |                              |                |                    |
| <b>2. Grant Number:</b> 1115-KEN-12b-X  |                              |                |                    |
| <b>3. Date of Decision Letter:</b> 18 December 2014   |                              |                |                    |
| <b>4. Date of the Partnership Framework Agreement:</b> 25 November 2014   |                              |                |                    |
| <b>5. Programme Title:</b> New Vaccine Support  |                              |                |                    |
| <b>6. Vaccine type:</b> Pneumococcal  |                              |                |                    |
| <b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV10), 10 dose(s) per vial , LIQUID |                              |                |                    |
| <b>8. Programme Duration<sup>1</sup>:</b> 2010 - 2015   |                              |                |                    |
| <b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>                  |                              |                |                    |
|   | 2010-2014                    | 2015           | Total <sup>2</sup> |
| Programme Budget (US\$)   | US\$134,519,856 <sup>3</sup> | US\$19,126,000 | US\$153,645,856    |
| <b>10. Vaccine Introduction Grant:</b> n/a  |                              |                |                    |
| <b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b>         |                              |                |                    |
| Type of supplies to be purchased with Gavi funds in each year   | 2010-2014                    | 2015           |                    |
| Number of Pneumococcal vaccines doses   |                              | 4,648,400      |                    |
| Number of AD syringes   |                              | 4,897,500      |                    |
| Annual Amounts (US\$)   | US\$134,519,856 <sup>5</sup> | US\$19,126,000 |                    |
| <b>12. Procurement agency:</b> UNICEF   |                              |                |                    |
| <b>13. Self-procurement:</b> n/a  |                              |                |                    |

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

<sup>5</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations: Reference code: 1115-KEN-12b-X-C**

According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

| Type of supplies to be purchased with Country funds in each year | 2015        |
|--|-------------|
| Number of vaccine doses  | 284,000     |
| Value of vaccine doses (US\$)                                    | US\$958,085 |
| Total Co-Financing Payments (US\$) (including freight)           | US\$986,500 |

**15. Operational support for campaigns:** n/a

**16. Additional documents to be delivered for future disbursements:**

| Reports, documents and other deliverables | Due dates   |
|---|-------------|
| Annual Progress Report or its equivalent  | 15 May 2015 |

**17. Financial Clarifications:** n/a

**18. Other conditions:** n/a

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
18 December 2014

## KENYA – ROTAVIRUS VACCINE SUPPORT

**This Decision Letter sets out the Programme Terms of a Programme.**

|   |                            |               |                    |
|---|----------------------------|---------------|--------------------|
| <b>1. Country:</b> Kenya  |                            |               |                    |
| <b>2. Grant Number:</b> 1415-KEN-13b-X  |                            |               |                    |
| <b>3. Date of Decision Letter:</b> 18 December 2014   |                            |               |                    |
| <b>4. Date of the Partnership Framework Agreement:</b> 25 November 2014   |                            |               |                    |
| <b>5. Programme Title:</b> New Vaccine Programme  |                            |               |                    |
| <b>6. Vaccine type:</b> Rotavirus   |                            |               |                    |
| <b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose(s) schedule              |                            |               |                    |
| <b>8. Programme Duration<sup>1</sup>:</b> 2014 - 2015   |                            |               |                    |
| <b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>          |                            |               |                    |
|   | 2014                       | 2015          | Total <sup>2</sup> |
| Programme Budget (US\$)   | US\$3,474,000 <sup>3</sup> | US\$9,540,500 | US\$13,014,500     |
| <b>10. Vaccine Introduction Grant:</b> n/a  |                            |               |                    |
| <b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b> |                            |               |                    |
| Type of supplies to be purchased with Gavi funds in each year   | 2014                       | 2015          |                    |
| Number of Rotavirus vaccines doses  |                            | 3,583,500     |                    |
| Annual Amounts (US\$)   | US\$3,474,000 <sup>5</sup> | US\$9,540,500 |                    |
| <b>12. Procurement agency:</b> UNICEF   |                            |               |                    |
| <b>13. Self-procurement:</b> n/a  |                            |               |                    |

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

<sup>5</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations: Reference code: 1415-KEN-13b-X-C** - According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

|  |             |
|--|-------------|
| Type of supplies to be purchased with Country funds in each year | 2015        |
| Number of vaccine doses  | 292,500     |
| Value of vaccine doses (US\$)                                    | US\$746,072 |
| Total Co-Financing Payments (US\$) (including freight)           | US\$775,500 |

**15. Operational support for campaigns:** n/a

**16. Additional documents to be delivered for future disbursements:**

| Reports, documents and other deliverables | Due dates   |
|---|-------------|
| Annual Progress Report or its equivalent  | 15 May 2015 |

**17. Financial Clarifications:** n/a

**18. Other conditions:** n/a

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
18 December 2014

## KENYA – YELLOW FEVER VACCINE SUPPORT

**This Decision Letter sets out the Programme Terms of a Programme.**

|   |                          |            |                    |
|---|--------------------------|------------|--------------------|
| <b>1. Country:</b> Kenya  |                          |            |                    |
| <b>2. Grant Number:</b> 0715-KEN-06b-X  |                          |            |                    |
| <b>3. Date of Decision Letter:</b> 18 December 2014   |                          |            |                    |
| <b>4. Date of the Partnership Framework Agreement:</b> 25 November 2014   |                          |            |                    |
| <b>5. Programme Title:</b> New Vaccine Support  |                          |            |                    |
| <b>6. Vaccine type:</b> Yellow Fever  |                          |            |                    |
| <b>7. Requested product presentation and formulation of vaccine:</b> Yellow Fever, 10 dose(s) per vial, LYOPHILISED |                          |            |                    |
| <b>8. Programme Duration<sup>1</sup>:</b> 2001 - 2015   |                          |            |                    |
| <b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>              |                          |            |                    |
|   | 2001-2014                | 2015       | Total <sup>2</sup> |
| Programme Budget (US\$)   | US\$370,410 <sup>3</sup> | US\$28,500 | US\$398,910        |
| <b>10. Vaccine Introduction Grant:</b> n/a  |                          |            |                    |
| <b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b>     |                          |            |                    |
|   | 2001-2014                | 2015       |                    |
| Type of supplies to be purchased with Gavi funds in each year   |                          |            |                    |
| Number of Yellow Fever vaccines doses   |                          | 25,200     |                    |
| Number of AD syringes   |                          | 23,900     |                    |
| Number of re-constitution syringes  |                          | 5,300      |                    |
| Annual Amounts (US\$)   | US\$370,410 <sup>5</sup> | US\$28,500 |                    |
| <b>12. Procurement agency:</b> UNICEF   |                          |            |                    |

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

<sup>5</sup> This is the consolidated amount for all previously approved years.

|  |             |
|--|-------------|
| <b>13. Self-procurement:</b> n/a   |             |
| <b>14. Co-financing obligations:</b> Reference code: 0715-KEN-06b-X-C  |             |
| According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.   |             |
| Type of supplies to be purchased with Country funds in each year   | 2015        |
| Number of vaccine doses  | 22,200      |
| Value of vaccine doses (US\$)  | US\$22,197  |
| Total Co-Financing Payments (US\$) (including freight)   | US\$24,000  |
| <b>15. Operational support for campaigns:</b> n/a  |             |
| <b>16. Additional documents to be delivered for future disbursements:</b>  |             |
| Reports, documents and other deliverables  | Due dates   |
| Annual Progress Report or its equivalent   | 15 May 2015 |
| <b>17. Financial Clarifications:</b> n/a   |             |
| <b>18. Other conditions:</b>   |             |
| * There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country. |             |

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
18 December 2014